Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) has asked the U.S. Food and Drug Administration to grant Rare Pediatric Disease Designation for its experimental SkinJect therapy in patients with …
ICYMI: Medicus Seeks FDA Rare Disease Status for Skin Cancer Therapy Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has asked the U.S. Food and Drug Administration to grant Rare Pediatric Disease Designation for SkinJect, its experimental treatment for patients with …
Medicus Seeks FDA Rare Disease Status for Skin Cancer Therapy Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted an application to health regulators in Abu Dhabi to begin a genomics-based Phase 2a study of its investigational drug Teverelix …
Medicus Seeks UAE Approval for Genomics-Based Endometriosis Trial Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted a registrational study protocol to the U.S. Food and Drug Administration for its SkinJect therapy in Gorlin syndrome, a rare …
ICYMI: Medicus Advances SkinJect Into Registrational Study for Rare Disorder Read More
PHILADELPHIA, PA — Medicus Pharma (Nasdaq: MDCX) has advanced its SkinJect® treatment into registrational development for Gorlin Syndrome, a rare genetic disorder that causes recurring skin cancers and often requires …
Medicus Pharma Seeks FDA Path for Rare Skin Cancer Disorder Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has secured access to up to $22 million in new financing, providing the biotechnology company with additional capital to fund clinical development …
Medicus Secures $22 Million Financing to Extend Cash Runway Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported expanded Phase 2 data for its SkinJect skin cancer therapy and advanced development of its Teverelix prostate cancer program during the …
Medicus Advances Cancer Pipeline as Losses Widen Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported additional Phase 2 trial data showing higher-dose treatment with its experimental SkinJect therapy produced stronger response rates in patients with nodular …
Medicus Pharma (Nasdaq: MDCX) Advances Lead Skin Cancer Regimen Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported additional Phase 2 trial data showing a dose-response relationship for its SkinJect treatment candidate for nodular basal cell carcinoma, with the …
Medicus Pharma Reports Expanded Phase 2 Skin Cancer Trial Data Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said its chief executive and leadership team met with U.S. lawmakers on Capitol Hill last month to seek support for regulatory and …
Medicus Pharma Meets Lawmakers to Advance SkinJect Program Read More